Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olverembatinib - Ascentage Pharma

Drug Profile

Olverembatinib - Ascentage Pharma

Alternative Names: APG 1351; BCR-ABL TKI; D 824; GZD 824; HQP 1351; IBI-348

Latest Information Update: 08 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou Institutes of Biomedicine and Health
  • Developer Ascentage Pharma; Innovent Biologics
  • Class Antineoplastics; Benzamides; Fluorinated hydrocarbons; Piperazines; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Cytokine inhibitors; Fms-like tyrosine kinase 3 inhibitors; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours; Chronic myeloid leukaemia; Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase III Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Gastrointestinal stromal tumours; Solid tumours
  • Preclinical Acute myeloid leukaemia; COVID 2019 infections; Renal cell carcinoma

Most Recent Events

  • 05 Mar 2024 Pharmacodynamics data from a preclinical study in Cancer released by Ascentage Pharma
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Chronic-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in USA (PO)
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Chronic-myeloid-leukaemia(Monotherapy, Second-line therapy or greater) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top